IL－2／TNF／LAK／TIL治疗晚期肺癌的近期疗效及免疫机理研究  

EFFICACY AND IMMUNOLOGICAL MECHANISM OF IL-2/TNF/LAK/TIL IN TREATMENT OF LUNG CARCINOMA

作　　者：周建英[1] 刘敬东[1] 程瑛[1] 何正善 孙永良[1] 姚航平[1] 林舜华[1] 何南祥[1] 

机构地区：[1]浙江医科大学附属第一医院肺科,浙江医科大学传染病研究所免疫研究室

出　　处：《浙江医科大学学报》1995年第2期66-69,共4页

摘　　要：作者报道用ＩＬ－２／ＴＮＦ／ＬＡＫ／ＴＩＬ治疗３０例失去手术机会和不能耐受全程化疗的晚期肺癌的结果。该法总有效率（ＣＲ＋ＰＲ）达４３．３％，９例伴有恶性胸水者经ＩＬ－２／ＴＮＰ／ＴＩＬ局部胸腔治疗后显效５例，有效４例。文中对该疗法的免疫机理作了初步探讨。The patients with advanced lung carcinoma who did not accept operations or respond to chemotherapy were treated with interleukin-2(IL-2) /tumor necrosis factor(TNF )/lymphokine-activated killing cells(LAK)and tumor infiltrating lymphocytes(TIL). The response rate (CR+PR)was 43.3%. Among them 9 patients with malignant pleural effusion underwent intrapleural administration of IL-2/TNF/TIL. Pleural effusion disappeared completely in 5 cases,and almost completely in 4.The immunological mechanism of this therapy was also discussed.

关 键 词：支气管肿瘤 白细胞介素 肿瘤坏死因子 杀伤细胞 

分 类 号：R734.105[医药卫生—肿瘤]